Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

Acceleron advances ACE-083 into the clinic
November 2014
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

CAMBRIDGE, Mass.—Biopharmaceutical company Acceleron Pharma Inc. has begun a Phase 1 trial of ACE-083, a novel muscle drug engineered to selectively increase muscle mass and strength in the muscles it is administered to by blocking proteins in the transforming growth factor-beta protein superfamily that modulate muscle growth. Acceleron is developing this investigational protein therapeutic for diseases in which improved muscle strength stands to provide a clinical benefit, such as certain forms of muscular dystrophy and inclusion body myositis.

“There is enormous unmet medical need to treat patients suffering from muscular and neuromuscular diseases, such as some forms of muscular dystrophy, and we believe that ACE-083 has the potential to treat a wide array of diseases in which patients have lost muscle mass and strength in specific muscles or muscle groups,” Dr. John Knopf, CEO of Acceleron, said in a news release.
 
Code:

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.